Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 1223 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
+ 673 more sites in the U.S.
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- HonorHealth — Phoenix, Arizona
- Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center — Burbank, California
+ 83 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Locations: - Alaska Womens Cancer Care Akwcc — Anchorage, Alaska
- University of Arizona Cancer Center — Tucson, Arizona
- City of Hope Medical Center — Duarte, California
+ 59 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Locations: - Alaska Women's Cancer Care — Anchorage, Alaska
- Yale University School of Medicine — New Haven, Connecticut
- Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida
+ 40 more sites in the U.S.
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…
Sponsor: AstraZeneca
NCT ID: NCT07218809
Locations: - Research Site — Birmingham, Alabama
- Research Site — Little Rock, Arkansas
- Research Site — La Jolla, California
+ 37 more sites in the U.S.
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Locations: - HonorHealth — Phoenix, Arizona
- University of Arkansas — Little Rock, Arkansas
- UCLA Health — Los Angeles, California
+ 35 more sites in the U.S.
Phase 3 Recruiting Industry
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Locations: - University of Alabama at Birmingham ( Site 0006) — Birmingham, Alabama
- Alaska Women's Cancer Care ( Site 0096) — Anchorage, Alaska
- UCSF Medical Center at Mission Bay ( Site 0013) — San Francisco, California
+ 34 more sites in the U.S.
Phase 3 Recruiting Industry
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Locations: - Disney Family Cancer Center — Burbank, California
- Scripps Clinic — La Jolla, California
- Palo Alto Medical Foundation — Palo Alto, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Locations: - University of Alabama - Birmingham ( Site 0058) — Birmingham, Alabama
- John Muir Health Cancer Center ( Site 0069) — Walnut Creek, California
- Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida
+ 24 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Locations: - University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- Cleveland Clinic Foundation - Florida — Weston, Florida
- Massachusetts General Hospital — Boston, Massachusetts
+ 10 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 pr…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT07546500
Locations: - Site 0107 — Phoenix, Arizona
- Site 0110 — Antioch, California
- Site 0104 — Beverly Hills, California
+ 9 more sites in the U.S.